A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

You'd hardly know it with the recent streak of summer weather, but we're weeks away from colder days when respiratory viruses ...

Pneumonia may inflame the air sacs in one or both of your lungs, notes the Mayo Clinic. The sacs can fill with pus or fluid, ...

Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of ...

Tuesday's approval makes Abrysvo the first RSV vaccine indicated for adults younger than 50, the biopharmaceutical company said. Last year, it was approved for use by those 60 years and older, as well ...

The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at ...

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or ...

The CDC said the cases of Mycobacterium pneumoniae in kids ages 2-4 are notable because the illness "historically hasn't been recognized as a leading cause of pneumonia in this age group." Plus: ...

Despite being back in the season of sniffles and sick days, Washington state will be extra equipped to battle the spread of respiratory viruses this year.